Erlotinib in the treatment of advanced non-small cell lung cancer: An update for clinicians

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 1, 2012, Pages 19-29

  Wang, Yongsheng ^a   Zhou, Caicun ^a   Schmid Bindert, Gerald ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

clinical trials; erlotinib; first line; non small cell lung cancer; treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; VASCULOTROPIN;

ADVANCED CANCER; ANEMIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; GENE EXPRESSION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863062587     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011427927     Document Type: Review

References (44)

1. Baselga J. Rischin D. Ranson M. Calvert H. Raymond E. Kieback D.G. et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292–4302.
2. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczesna A. Juhasz E. et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology, 11: 521–529.
3. Coudert B. Ciuleanu T. Park K. Wu Y.L. Giaccone G. Brugger W. et al. (2011) Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol, in press.
4. Crino L. Cappuzzo F. Zatloukal P. Reck M. Pesek M. Thompson J.C. et al. (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26: 4253–4260.
5. Gandara D.R. Gumerlock P.H. (2005) Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 23: 5856–5858.
6. Gatzemerier U. Pluzanska A. Szczesna A. Kaukel E. Roubec J. de Rosa F. et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25: 1545–1552.
7. Giaccone G. Herbst R.S. Manegold C. Scagliotti G. Rosell R. Miller V. et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol, 22: 777–784.
8. Giaccone G. Gallegos Ruiz M. Le Chevalier T. Thatcher N. Smit E. Rodriguez J.A. et al. (2006) Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12: 6049–6055.
9. Goss G. Ferry D. Wierzbicki R. Laurie S.A. Thompson J. Biesma B. et al. (2009) Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 27: 2253–2260.
10. Gridelli C. Maione P. Rossi A. Ferrara M.L. Bareschino M.A. Schettino C. et al. 2009. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14: 137–147.
11. Hensing T.A. Schell M.J. Lee J.H. Socinski M.A. (2005) Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 47: 253–259.
12. Herbst R.S. Maddox A.M. Rothenberg M.L. Small E.J. Rubin E.H. Baselga J. et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815–3825.
13. Herbst R.S. Giaccone G. Schiller J.H. Natale R.B. Miller V. Manegold C. et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol, 22: 785–794.
14. Herbst R.S. Prager D. Hermann R. Fehrenbacher L. Johnson B.E. Sandler A. et al. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892–5899.
15. Hesketh P.J. Chansky K. Wozniak A.J. Hirsch F.R. Spreafico A. Moon J. et al. (2008) Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 3: 1026–1031.
16. Hidalgo M. Siu L.L. Nemunaitis J. Rizzo J. Hammond L.A. Takimoto C. et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267–3279.
17. Higgins B. Kolinsky K. Smith M. Beck G. Rashed M. Adames V. et al. (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15: 503–512.
18. Hirsch F.R. Kabbinavar F. Eisen T. Martins R. Schnell F.M. Dziadziuszko R. et al. (2011) A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 29: 3567–3573.
19. Jemal A. Siegel R. Ward E. Hao Y. Xu J. Thun M.J. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
20. Kabbinavar F. Miller V. Johnson B. O'Connor P. Soh C. (2010) Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28: 15s (suppl; abstr 7526).
21. Lee J. Park K. Kim S. Lee D. (2009) A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. 13th Biennial World Conference on Lung Cancer of the International Association of the Study of Lung Cancer (IASLC); San Francisco 2009.
22. Lee D.H. Kim S.W. Suh C. Han Y.H. Lee J.S. (2011) Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother Pharmacol 67: 35–39.
23. Lynch T.J. Bell D.W. Sordella R. Gurubhagavatula S. Okimoto R.A. Brannigan B.W. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
24. Maemondo M. Inoue A. Kobayashi K. Sugawara S. Oizumi S. Isobe H. et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388.
25. Miller V. O'Connor P. Soh C. Kabbinavar F. (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27: 18s (suppl; abstr LBA8002).
26. Mitsudomi T. Morita S. Yatabe Y. Negoro S. Okamoto I. Tsurutani J. et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121–128.
27. Mok T.S. Wu Y.L. Thongprasert S. Yang C.H. Chu D.T. Saijo N. et al. (2009 a) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
28. Mok T.S. Wu Y.L. Yu C.J. Zhou C. Chen Y.M. Zhang L. et al. (2009 b) Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27: 5080–5087.
29. Niho S. Kubota K. Goto K. Yoh K. Ohmatsu H. Kakinuma R. et al. (2006) First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 24: 64–69.
30. Normanno N. Bianco C. de Luca A. Maiello M.R. Salomon D.S. (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1–21.
31. Paez J.G. Janne P.A. Lee J.C. Tracy S. Greulich H. Gabriel S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
32. Pollack V.A. Savage D.M. Baker D.A. Tsaparikos K.E. Sloan D.E. Moyer J.D. et al. (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739–748.
33. Rinaldi M. Cauchi C. Gridelli C. (2006) First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17(Suppl. 5): v64-v67.
34. Rosell R. Gervais R. Vergnenegre A. Massuti B. Felip E. Cardenal F. et al. (2011) Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 29(Suppl.): abstract 7503.
35. Schiller J.H. Harrington D. Belani C.P. Langer C. Sandler A. Krook J. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.
36. Shepherd F.A. Pereira J. Ciuleanu T.E. Tan E.H. Hirsh V. Thongprasert S. et al. (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1(st) line or 2(nd) line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 22: 622s–622s.
37. Shepherd F.A. Rodrigues Pereira J. Ciuleanu T. Tan E.H. Hirsh V. Thongprasert S. et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.
38. Siu L.L. Wong K.F. Chan J.K. Kwong Y.L. (1999) Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 155: 1419–1425.
39. Thatcher N. Chang A. Parikh P. Rodrigues Pereira J. Ciuleanu T. et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366: 1527–1537.
40. Yamamoto N. Kaira K. Naito T. Takahashi T. Ayabe E. Shimoyama R. et al. (2010) Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 68: 99–104.
41. Yang C.H. Yu C.J. Shih J.Y. Chang Y.C. Hu F.C. Tsai M.C. et al. (2008) Specific EGFR mutations predict treatment outcome of stage IIIB / IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26: 2745–2753.
42. Yang P. Allen M.S. Aubry M.C. Wampfler J.A. Marks R.S. Edell E.S. et al. (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128: 452–462.
43. Zhang L. Shenglin M. Song X. Han B. Cheng Y. Huang C. et al. (2011) Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 29(Suppl.): abstract LBA7511.
44. Zhou C. Wu Y.L. Chen G. Feng J. Liu X.Q. Wang C. et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742.